Skip to main content

TALPHERA INC

For the period ended Dec 31, 2023. Filed Mar 6, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 6, 2024

TLPH$1.05-3.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 15. Exhibits and Financial Statement Schedules

1.Financial Statements:

See Index to Financial Statements in Item 8 of this Form 10-K.

2.Financial Statement Schedules:

Reference is made to the financial statement schedules included under Item 8 of Part II hereof. All other schedules are omitted because they are not applicable, not required or the information is shown in the financial statements or the notes thereto.

(b)Exhibits
Incorporation By Reference
Exhibit NumberExhibit DescriptionFormSEC File No.ExhibitFiling Date
2.1§#Asset Purchase Agreement, between the Registrant and Vertical Pharmaceuticals, LLC, dated March 12, 2023.10-Q001-350682.111/14/2023
3.1Amended and Restated Certificate of Incorporation of the Registrant.8-K001-350683.102/18/2011
3.2Certificate of Amendment to the Amended and Restated Certificate of Incorporation, dated January 9, 20248-K001-350683.101/09/2024
3.3Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant.8-K001-350683.106/25/2019
3.4Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant.8-K001-350683.110/25/2022
3.5Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock of the Registrant.8-K001-350683.108/04/2022
3.6Certificate of Elimination of Series A Convertible Preferred Stock of the Registrant.8-K001-350683.210/25/2022
3.7Amended and Restated Bylaws of the Registrant.8-K001-350683.101/09/2024
4.1Description of Capital Stock.10-K001-350684.103/15/2021
4.2Reference is made to Exhibits 3.1 through 3.4.
4.3Specimen Common Stock Certificate of the Registrant.S-1333-1705944.201/31/2011
4.4Form of Warrant to Purchase Common Stock of the Registrant, dated as of May 30, 2019.8-K001-350684.106/03/2019
4.5Form of Warrant to Purchase Common Stock of the Registrant, dated as of November 15, 2021.8-K001-350684.111/15/2021
4.6Warrant to Purchase Common Stock of the Registrant, dated as of August 3, 2022.8-K001-350684.108/04/2022
4.7Form of Common Warrant (December 2022).8-K001-350684.112/28/2022
4.8Form of Pre-Funded Warrant (December 2022).8-K001-350684.212/28/2022
4.9Form of Common Warrant, as amended (November 2022).8-K001-350684.312/28/2022
10.1+Form of Indemnification Agreement between the Registrant and each of its directors and executive officers.S-1333-17059410.101/07/2011
10.2+2011 Equity Incentive Plan.S-8333-17240999.302/24/2011
10.3+Forms of Stock Option Grant Notice, Notice of Exercise and Option Agreement under 2011 Equity Incentive Plan.10-K001-3506810.503/30/2011
10.4+Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under 2011 Equity Incentive Plan.10-K001-3506810.603/30/2011
10.5+Amended and Restated 2020 Equity Incentive Plan.8-K001-35068310.106/17/2021
10.6+Forms of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the Amended and Restated 2020 Equity Incentive Plan.S-8333-23921399.206/16/2020
10.7+Forms of RSU Award Grant Notice and Award Agreement (RSU Award) under the Amended and Restated 2020 Equity Incentive Plan.S-8333-23921399.306/16/2020
10.8+Amended and Restated 2011 Employee Stock Purchase Plan.S-8333-23921399.406/16/2020
10.9+Amended and Restated Offer Letter between the Registrant and Badri (Anil) Dasu, dated December 30, 2010.S-1333-17059410.1501/07/2011
10.10+Amended and Restated Offer Letter between the Registrant and Pamela Palmer, dated December 29, 2010.S-1333-17059410.1601/07/2011
10.11+Offer Letter between the Registrant and Vincent J. Angotti, effective as of March 6, 2017.10-Q001-3506810.405/08/2017
10.12+Offer Letter between the Registrant and Raffi Asadorian, dated July 18, 2017.8-K001-3506810.107/19/2017
10.13+Amended and Restated Severance Benefit Plan effective as of February 7, 2017.8-K001-3506810.202/09/2017
10.14§#Commercial Supply Agreement, effective March 31, 2021 by and between the Registrant and Catalent Pharma Solutions, LLC.10-Q001-3506810.108/16/2021
10.15§#License and Commercialization Agreement (DZUVEO), dated July 14, 2021, between the Registrant and Laboratoire Aguettant.10-Q001-3506810.111/15/2021
10.16§#License and Commercialization Agreement (PFS), dated July 14, 2021, between the Registrant and Laboratoire Aguettant.10-Q001-3506810.211/15/2021
10.17Contingent Value Rights Agreement, dated as of January 7, 2022, by and among the Registrant, James Wilkie, solely in his capacity as the representative of the Lowell stockholders and option holders, and Computershare Inc., and its wholly-owned subsidiary, Computershare Trust Company, N.A., a federally chartered trust company, collectively as Rights Agent.8-K001-3506810.101/12/2022
10.18Controlled Equity OfferingSM Sales Agreement between the Registrant and Cantor Fitzgerald & Co., dated as of June 21, 2016.8-K001-3506810.106/21/2016
10.19Amendment No. 1 to the Controlled Equity OfferingSM Sales Agreement between the Registrant and Cantor Fitzgerald & Co., dated as of August 29, 2020.S-3333-2391561.306/12/2020
10.20Loan and Security Agreement between the Registrant and Oxford Finance, LLC, dated as of May 30, 2019.8-K001-3506810.106/03/2019
10.21First Amendment to Loan and Security Agreement between the Registrant and Oxford Finance, LLC, dated as of May 5, 2021.10-Q001-3506810.411/15/2021
10.22Second Amendment to Loan and Security Agreement between the Registrant and Oxford Finance, LLC, dated as of November 14, 2021.10-K001-3506810.3103/10/2022
10.23Registration Rights Agreement, between the Registrant and Lincoln Park Capital Fund, LLC, dated as of August 3, 2022.8-K001-3506810.208/04/2022
10.24Form of Securities Purchase Agreement, by and among the Registrant and the Purchasers, dated as of July 17, 2023.8-K001-3506810.107/21/2023
10.25Form of Registration Rights Agreement, by and among the Registrant and the Purchasers, dated as of July 17, 2023.8-K001-3506810.207/21/2023
10.26Form of Series A common stock warrant (July 2023).8-K001-3506810.307/21/2023
10.27Form of Series B common stock warrant (July 2023).8-K001-3506810.407/21/2023
10.28Form of Pre-Funded Warrant (July 2023).8-K001-3506810.507/21/2023
10.29Form of placement agent Series A common stock warrant.8-K001-3506810.607/21/2023
10.30Form of placement agent Series B common stock warrant.8-K001-3506810.707/21/2023
10.31Form of Securities Purchase Agreement, by and among the Registrant and entities affiliated with Nantahala Management, LLC, dated as of January 17, 2024.8-K001-3506810.101/22/2024
10.32Form of Securities Purchase Agreement, by and among the Registrant and Investor Company ITF Rosalind Master Fund L.P., dated as of January 17, 2024.8-K001-3506810.201/22/2024
10.33Form of Registration Rights Agreement, between the Registrant and the Purchasers, dated as of January 17, 2024.8-K001-3506810.301/22/2024
10.34Form of Pre-Funded Warrant (January 2024).8-K001-3506810.401/22/2024
23.1Consent of BPM LLP, Independent Registered Public Accounting Firm.
23.2Consent of Withum Smith & Brown LLP, Independent Registered Public Accounting Firm.
24.1Power of Attorney (included in signature page).
31.1Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.
31.2Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.
32.1Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
97+Talphera, Inc. Incentive Compensation Recoupment Policy.
101.INSXBRL Instance Document- the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHInline XBRL Taxonomy Schema Document
101.CALInline XBRL Taxonomy Calculation Linkbase Document
101.DEFInline XBRL Taxonomy Definition Linkbase Document
101.LABInline XBRL Taxonomy Label Linkbase Document
101.PREInline XBRL Taxonomy Presentation Linkbase Document
104Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.INS, 101.SCH, 101.CAL, 101.DEF, 101.LAB, and 101.PRE).
§Schedules omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant agrees to furnish supplementally a copy of any omitted schedule upon request by the SEC.
+Indicates management contract or compensatory plan.
#Material in the exhibit marked with an “[*]” has been omitted because it is confidential, not material, and would be competitively harmful if publicly disclosed.

The certifications attached as Exhibit 32.1 accompany this Annual Report on Form 10-K pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.